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Abstract Non-vitamin K antagonist oral anticoagulants
(NOACs) are replacing warfarin and heparins in several
clinical situations. With varying modes of action, the
effects of NOACs on thrombus formation, integrity, and
lysis is unknown. To determine whether two techniques of
thrombelastography (TEG) and a micro-plate assay (MPA)
provide novel data on thrombus formation, integrity and
lysis in those taking a NOACs compared to warfarin and a
control group taking aspirin. We assessed thrombogenesis,
clot integrity and fibrinolysis in blood (TEG) and plasma
(MPA) from 182 atrial fibrillation patients—50 on aspirin,
50 on warfarin, and 82 on a NOAC (17 apixaban, 19
dabigatran and 46 rivaroxaban). Eleven of 16 TEG indices
and 4 of 5 MPA indices differed (p B 0.01) between those
on aspirin, warfarin or a NOAC. Three TEG indices and 4
MPA indices differed (p\ 0.01) between the NOACs.
Time to initiation of clot formation was most rapid on
apixaban, then rivaroxaban and slowest on dabigatran. The
rate of clot formation was most rapid on dabigatran, then
apixaban, and slowest on rivaroxaban. Clot density was
greatest on rivaroxaban, then apixaban, but weakest on
dabigatran. The rate of clot dissolution was most rapid in
apixaban, then dabigatran, and slowest on rivaroxaban. The
TEG and MPA identify major differences in thrombogen-
esis and fibrinolysis in different NOACs. These techniques
may have value in investigating the effects of these drugs
on haemostasis in a clinical setting, and in identifying those
in need of targeted therapy.
Keywords Atrial fibrillation  Fibrinolysis  NOAC 
Thrombelastograph  Thrombosis
Abbreviations
INR International normalised ratio
MA Maximum amplitude
MOD Maximum optical density
MPA Micro-plate assay
NOAC Non-vitamin K antagonist anticoagulant
OD Optical density
RCD Rate of clot dissolution
RCF Rate of clot formation
TEG Thrombelastograph
tPA Tissue plasminogen activator
T50 Time for 50 % of the clot to be lysed
VKA Vitamin K antagonist
Introduction
The introduction of non-vitamin K antagonist oral antico-
agulants (NOACs) has fundamentally changed clinical
practice in the use of oral and parenteral anticoagulation
therapy in the prevention of stroke in atrial fibrillation
(AF), and in the prevention and treatment of venous
thromboembolism, including after orthopaedic surgery.
Unlike vitamin K antagonists (VKAs, such as warfarin),
which non-specifically suppress hepatic production of
functional coagulation factors II, VII, IX and X by
inhibiting vitamin K metabolism, NOACs target specific
molecules of the coagulation cascade: dabigatran is a direct
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thrombin inhibitor whilst apixaban and rivaroxaban both
target factor Xa [1–4].
NOACs have several advantages over VKAs, one being
that their predictable pharmacokinetics allows for elimina-
tion of routine anticoagulation monitoring. However, there
are a small number of instances, such as in emergency sur-
gery and in suspected overdose, where precise knowledge of
the degree of anticoagulation is called for [4, 5]. Although
NOACs may in exceptional (emergency) circumstances be
assessed by standard laboratory tests (such as the pro-
thrombin time and the activated partial thromboplastin time),
lack of sensitivity and specificity of these tests calls for other
assays (such as ecarin clotting time and anti-Factor Xa
activity) [4–6]. A further feature of NOACs use is that renal
function must be assessed as use of these drugs require
caution in those with severe renal failure [7].
Other laboratory tools for determining the rate of
thrombus formation and fibrinolysis in whole blood and
plasma include techniques such as the thrombelastograph
(TEG) [8] and an assay performed in a 96-well microtitre
plate, of which there are several variants [9–11]. The TEG
delivers numerous indices, such as the time for coagulation
to begin, the rate of clot formation, the physical strength of
the clot, and the rate of auto-fibrinolysis, and has been used
to manage patients experiencing severe bleeding resulting
from the polytrauma of cardiac surgery, in renal disease,
and to compare anticoagulants [12–15]. Our recently
described microplate assay (MPA) [9] provides five similar
measures, including the time for coagulation to begin and
the rate of clot formation, but also on the density of the
fibrin clot and its resistance to fibrinolysis by exogenous
tissue plasminogen activator (tPA). The effect of the clin-
ical use of NOACs on these two techniques has yet to be
determined, and may provide novel perspectives on the
action of these drugs.
Therefore, we hypothesized that the TEG and MPA
methods will demonstrate difference in indices of clot
formation, integrity and lysis between blood and plasma
from those taking warfarin and the three commonly used
NOACs. We used AF as a model in which to test these
hypotheses, as in different clinical situations patients may
be on warfarin or on a NOAC. Furthermore, as AF patients
may be taking aspirin, these provide a control group of




Consecutive patients with AF were recruited from routine
out-patient cardiology clinics, and all had been taking their
anti-thrombotic for at least 4 weeks. Doses were according
to UK guidelines, e.g. apixaban 5 mg bd, dabigatran 150 mg
bd, rivaroxaban 20 mg od, warfarin titrated to achieve an
international normalised ratio (INR) between 2.0 and 3.0.
For those on warfarin, INR was determined on the day of
testing to assess effective anticoagulation. For those
receiving NOACs, venepuncture took place 4–6 h after the
daily dose of the drug. Exclusion criteria were age
\18 years, active or recent (\12 months) malignancy,
active immunological disease, pregnancy, chronic liver
disease, recent or chronic infections, chronic inflammatory
disease, connective tissue disease, recent stroke/acute coro-
nary syndrome (within 2 months), active bleeding, recent
arterial/venous thrombosis or recent surgery, known hae-
mophilia or thrombophilia (such as Factor V Leiden, Protein
C/S/anti-thrombin deficiency, anti-phospholipid syndrome),
use of an anti-platelet agent other than aspirin, use of a VKA
other than warfarin, and dual anti-thrombotic therapy.
Standard clinical and demographic data were obtained, and a
routine blood test was taken for renal function. The project
has been approved by the Local Research Ethics Committee
and informed consent was obtained from each participant.
Laboratory
Citrated venous blood was collected by venepuncture and
analysed for indices of thrombogenesis and fibrinolysis
within 2 h of collection. The TEG was used according to the
manufacturer’s instructions. Thrombus formation and
autolysis were monitored for up to 60 min after the addition
of calcium to whole blood supplemented with kaolin, in
which cases it is methodologically allied to the activated
partial thromboplastin time (Fig. 1). Table 1 describes 16 of
the most appropriate TEG indices that can be summarised
as those pertaining to the initiation of thrombosis, the rate of
thrombus formation, the physical strength of the clot once
formed, and the rate of autolysis. For the MPA, citrated
plasma was obtained from venous sample by centrifugation
at 2500 rpm for 15 min [9]. The MPA, which is conducted
at 37 C throughout, consists of two parts. Firstly, in a
thrombogenesis assay, 25 ll plasma, 75 ll TRIS-NaCl
buffer, and 50 ll thrombin/calcium are added to the wells of
96-well microtitre plate in triplicate (final concentration of
thrombin in the reaction vessel = 0.473 IU/ml). Clot for-
mation is followed for 30 min in a vibrating micro-titre
plate reader by changes in optical density (Fig. 2a). Sec-
ondly, the fibrinolysis assay calls for 75 lL of plasma and
75 lL of a Tris/NaCl/calcium buffer supplemented with
thrombin and tPA (final concentration of tPA in the reaction
vessel = 10 lg/ml). The plate is immediately loaded into
the plate reader as for the thrombogenesis assay, and data
collected for 30 min. The data is post-processed to plot into
line charts, and from these the rate of clot dissolution (RCD)
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and the time for 50 % of the clot to lyse (T50) are calcu-
lated. The RCD is defined as the fall in optical density from
its maximum (peak) value to the elbow point, divided by the
time between these two points. The T50 is defined as the
half of the time interval between the peak and the elbow
point (Fig. 2b).
The five indices produced by the MPA also reflect clot
formation, density and lysis (Table 1), and reflect several
of those of the TEG. For example, the TEG R time and
MPA L time both measure time taken for thrombogenesis
to begin. The TEG K time marks time from the beginning
of clot formation to when a fixed level of clot firmness is
reached: there is no MPA equivalent of this index. The
TEG angle and the MPA rate of clot formation (RCF) both
measure the rate clot growth. The TEG maximum ampli-
tude (MA) and MPA maximum optical density (MOD)
respectively both assess maximum strength, stiffness or
density of the developed clot. The TEG LY and CL indices,
the MPA results of the RCD and the T50 all provide
indices of the ability of the formed clot to resist fibrinol-
ysis. Further details of the relationship between the TEG
and the MPA are presented elsewhere [9].
Statistical analysis
We hypothesised a difference in a continuously variable
test statistic of a third of a standard deviation between any
two of the major antithrombotic drug groups. For an overall
analysis of variance (ANOVA) of p\ 0.01 and p\ 0.05
between groups at 1 = beta = 0.8, then a sample size of
50 per group is required. We recruited consecutively until
this target was achieved. Upon completion, there were at
least 17 patients in each NOAC group. This sample size
provides the overall ANOVA of p\ 0.02, and p\ 0.05
between groups for a difference of half a standard deviation
at 1-beta = 0.8. Continuously variable data are expressed
as mean and standard deviation (SD) or median and
interquartile range (IQR) dependent on distribution, and
analysed by analysis of variance or the Kruskall–Wallis
test. Differences between groups were sought by Tukey’s
post hoc test (log transformed if necessary). Categorical
indices were analysed by the Chi squared test. Correlations
were sought using Spearman’s method. Analyses were
performed on Minitab 16, and, in view of the multiple
analyses, p B 0.01 was considered significant.
Fig. 1 A typical TEG printout. Typical TEG graphical tracing:
amplitude against time. A Amplitude, CI coagulation index, EPL
estimated potential lysis, G G-parameter, K K-time, LY30 percentage
of lysis 30 min post maximum amplitude is attained, MA maximum
amplitude, PMA projected maximum amplitude, R R-time. Figures are
manufacturer’s reference ranges
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Results
Clinical and demographic details of the 182 participants
managed by different antithrombotic agents are shown in
Table 2. There were no significant differences in age, sex,
blood pressure or renal function although there were pro-
portionally more patients with ischaemic heart disease in
the aspirin (34 %) and warfarin (42 %) groups compared to
those on a NOAC (21 %). Patients on warfarin had a higher
body mass index than those on aspirin. The mean INR was
2.6 (0.7) in those on warfarin.
Table 3 shows age, sex, renal function, TEG indices and
MPA indices in those on aspirin, warfarin or a NOAC.
Patients on aspirin had higher mean serum creatinine levels
than the two other groups but renal function was similar
between the warfarin and NOAC groups, probably
reflecting practitioners’ reluctance to place those with poor
renal function on a NOAC [5, 7]. There were differences in
11 of the 16 TEG indices: 7 were between the aspirin group
and the two other groups. For example, warfarin and (as a
whole) NOACs both extended the TMA by slightly under
20 %. TEG indices CL30, LY30, CL60 and LY60 differed
between those on warfarin and those in the combined
NOAC group. These four indices inter-correlated with
correlation coefficients between 0.91 and 0.99. In the 50
patients on patients on warfarin, the INR significantly
correlated with TEG indices of R time (r = 0.47,
p = 0.001), the TMA (r = 0.40, p = 0.004) and the CI
(r = -0.42, p = 0.003). The INR correlated with MPA
indices L time (r = 0.40, p = 0.004) and RCF (r = -0.57,
p\ 0.001).
Table 4 shows the same analysis of the 82 patients
taking one of the three NOACs. Only 3 TEG indices
differed between the NOACs. The R time (reflecting time
to the initiation of clot formation) was shorter in those on
apixaban than in those of dabigatran. Similarly, the TMA
(time taken for the clot to be at its strongest) was shorter
in those on apixaban (that being only 5.9 % longer than
the time taken by those on aspirin) than in those on
dabigatran (being 33.4 % longer than the time taken by
Table 1 TEG and MPA indices
Process assessing
TEG indices
R time Time from the initiation of the test until the point where the clot begins to form
K time Interval from the split point of the test to the point where the fibrin cross-linking provides enough clot resistance to produce
a 20-mm amplitude
Angle Angle formed by the slope of a tangent line traced from the R time to the K time: reflects the rate at which the clot forms
MA Maximum amplitude of the clot dynamics, reflecting clot strength
TMA Time to maximum amplitude (when the clot is strongest)
G Shear-elastic modulus of the strength of the clot
E Normalised G parameter
TPI Thrombo-dynamic potential index: The elastic shear modulus divided by kinetics of clot development, reflecting global
coagulation
A30 Amplitude (reflecting clot strength) after 30 min
CL30 Proportion of the clot (as a percentage) that remains unlysed after 30 min
LY30 Percentage of the clot that has lysed 30 min after the time of MA
A60 Amplitude (reflecting clot strength) after 60 min
CL60 Proportion of the clot (as a percentage) that remains unlysed lysed after 60 min
LY60 Percentage of the clot that has lysed 60 min after the time of MA
A Amplitude: measures the width of tracing at the latest time point
CI Coagulation index: assessment of overall coagulation derived from other indices including the R time, K time, MA and the
angle
MPA indices
L time Lag time from the initiation of the test to the start of clot formation
RCF Rate of clot formation: change in optical density over time from the beginning of clot formation to maximum optical
density
MOD Maximum optical density, reflecting clot thickness
RCD Rate of clot dissolution: reduction in optical density from maximum to the plateau phase
T50 Time for 50 % of the clot to lyse
TEG definitions as provided by manufacturer. Full details of MPA indices in Ref. [9]. See also Figs. 1 and 2
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those on aspirin). The CI (coagulation index, a global
score of haemostasis) was higher in those on apixaban
(and comparable to the CI of those on aspirin) when
compared to the CI of those on dabigatran. The MPA L
time (reflecting time to initiation of the clot) was shorter,
and the MOD (reflecting clot density) was greater in those
on apixaban and in those on rivaroxaban than in those of
dabigatran. The RCF (rate of clot formation) was slower
in those on rivaroxaban than in the two other NOACs.
The RCD (reflecting clot dissolution by exogenous tPA)
was slowest in those on rivaroxaban than in those on
apixaban.
Discussion
We report marked differences in the laboratory assessment
of thrombogenesis and fibrinolysis of blood and plasma
from patients on different NOACs. Despite best clinical
care, patients on anti-thrombotic therapy still suffer from
thrombosis and are at risk of haemorrhage, as exemplified
by difficulties in the management of warfarin [15–17].
Accordingly, the identification and targeted care of the
highest-risk patients is likely to be successful in reducing
the rate of an adverse end point, and the laboratory is best
placed to provide this information.
Fig. 2 Data from the MPA.
a Thrombogenesis. The plot
shows changes in optical
density as the fibrin clot forms
follwing initiation (time = 0 s).
Triplicate plots are shown.
b Fibrinolysis. The plot shows
changes in optical density as the
fibrin clot forms. Triplicate
plots are shown. T100 % is the
time to maximum absorbance,
T0 % is the return of the optical
density to near-baseline. T50 %
is (T100 %—T0 %)/2. The
slope is the sharpest fall in
optical density over time under
the effect of exogenous tPA,
effectively the reverse of the
rate of clot formation in a
Effects of non-vitamin K antagonist oral anticoagulants… 539
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Both the TEG and MPA methods provide data on clot
formation and lysis that differ according to the anti-
thrombotic drug. Seven TEG indices were different in
blood taken from patients taking an OAC compared to
those (on aspirin) whose coagulation pathway should be
intact, and are therefore to be expected. Five indices were
no different between the anti-thrombotics, calling into
doubt their value in this setting. Although CL30, LY30,
CL60, LY60 were different between those on warfarin and
those on a NOAC, there was no difference in these indices
in those on a NOAC compared to those on aspirin. Fur-
thermore, with correlation coefficients between 0.91 and
0.99, these four indices are effectively delivering the same
information. We interpret this as that the warfarin clot is
less robust and faster to auto-lyse than the NOAC clot. In
this respect the LY indices offer better discrimination than
the CL indices. Three MPA indices reflecting time for clot
formation to begin, the rate of clot formation, and clot
density were understandably equally altered in oral anti-
coagulation use compared to aspirin. However, the T50
index was different between each of the three groups.
Although the fibrin clot in those on warfarin was more
susceptible to lysis by exogenous tPA (i.e. a shorter T50)
than the clot in those on aspirin, the clot in those on a
NOAC was significantly more susceptible to lysis.
The TEG R time and MPA L time both assess time for
coagulation to begin. Compared to blood and plasma from
patient on aspirin (and therefore likely to have an intact
coagulation pathway), apixaban impeded initiation of
thrombogenesis by an average of 37 and 45 % respectively,
rivaroxaban by 75 and 78 % respectively, but dabigatran
was the most effective NOAC, impeding these times by
118 to 318 % respectively. In this setting, we suggest
dabigatran is the most effective NOAC. The TEG TMA
and MPA RCF assess the rate of thrombogenesis. Dabi-
gatran was least effective in interfering with thrombogen-
esis, inhibiting 29 % of rate of clot formation when
compared to ‘normal’ thrombogenesis (i.e. when on
aspirin), whilst rivaroxaban had the greatest influence of
slowing thrombogenesis, giving a result (69 % inhibition)
close to that of warfarin (65 % inhibition). In this respect,
we suggest rivaroxaban is the most effective NOAC. The
global TEG CI (coagulation index) sums several indices
reflecting different aspects of thrombogenesis, including
the R time, K time, MA and the angle. The result for
apixaban was the same as that for aspirin, suggesting poor
overall anticoagulation, whereas that for rivaroxaban was
the same as for warfarin, suggesting overall equal effect.
However, the increased CI figure for dabigatran suggests
this NOAC has better overall function as an anticoagulant.
The MPA index MOD reflects clot density, whilst the
RCD reflects the ease of digestion of the clot by tPA.
Plasma from those on rivaroxaban produced the clot with
the greatest density (close to that of those on aspirin) and
the clot most resistant to digestion (result again close to
that of aspirin). Dabigatran produced the least dense clot,
whilst apixaban produced a clot that was most susceptible
to thrombolysis. Despite the short T50 (reflecting rapid clot












Age (years) 73.3 (13.2) 73.9 (9.0) 72.1 (10.6) 76.9 (10.6) 71.6 (8.5) 0.443
Sex (male/female) 37/13 32/18 8/9 15/4 26/20 0.122
SBP (mm Hg) 130 (18) 130 (19) 135 (18) 126 (22) 132 (18) 0.641
DBP (mm Hg) 74 (13) 73 (12) 76 (14) 73 (15) 73 (11) 0.915
BMI (kg/m2) 26.1 (5.6) 29.6 (4.3) 27.4 (5.3) 26.7 (4.3) 30.1 (7.3) 0.004
Creatinine (lmol/l) 103 (51) 87 (15) 86 (30) 90 (22) 88 (21) 0.082
eGFR (ml/min/1.73) 64 (21) 70 (10) 68 (19) 71 (14) 69 (15) 0.265
IHD (yes/no) 17/33 21/29 3/14 6/13 8/38 0.007
Smoking (yes/no) 3/47 1/49 0/17 1/18 3/43 *
Diabetes (yes/no) 8/42 16/34 6/11 3/19 12/34 0.196
Hypertension (yes/no) 42/8 43/7 15/2 14/5 33/13 0.302
Heart failure (yes/no) 10/40 15/35 1/16 1/18 10/36 0.099
Valve disease (yes/no) 1/49 3/47 0/17 0/19 3/43 *
Pulmonary disease (yes/
no)
5/45 4/46 3/14 1/18 5/41 0.762
Data presented as mean (standard deviation) or number of patients. p values by analysis of variance or the Chi squared test. SBP systolic blood
pressure, DBP diastolic blood pressure, BMI body mass index, eGFR estimated glomerular filtration rate, IHD ischaemic heart disease
*Analysis unreliable
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lysis) of all subjects on a NOAC compared to aspirin and
warfarin users (Table 3), there was no difference between
the NOACs. These data on lysis are difficult to interpret in
a clinical setting. For example, it may be that a clot that is
dense and resistant to lysis is more likely to promote a
clinical thrombotic event, in that it is likely to remain
in situ for longer, and so less likely to promote haemor-
rhage. Conversely, a clot that is less dense and is quicker to
lyse may be less likely to transform into a clinically rele-
vant thrombus, but may instead promote haemorrhage. In
this respect, rivaroxaban produced formed clot dynamics
closest to that of aspirin.
A strength of our data is that it reflects real-world oral
anticoagulation use, controlled by samples from patients
with the same cardiovascular disease in whom (we believe)
the coagulation pathway is expected to be intact (i.e. are on
aspirin). Although Dias et al. [18] probed the effects of
NOACs, they spiked blood from healthy volunteers with a
NOAC and subsequently applied the blood to a TEG.
Neyens et al. [19] used a TEG to assess haemostasis in a
case report of a patient on dabigatran. However, we must
temper our conclusions in that (for clinical reasons) we
recruited far fewer patients on apixaban or on dabigatran
than on rivaroxaban, leading to possible false negatives in
comparing apixaban with dabigatran. Furthermore, the
marked correlations between many TEG indices (63 com-
parisons with an r[ 0.6) suggests that a high proportion of
these indices are redundant and add nothing to the value of
Table 3 Analysis according to
anti-thrombotic drug class
Aspirin (n = 50) NOAC (n = 82) Warfarin (n = 50) p
Clinical and demographic
Age (years) 73.7 (13.2) 73.5 (10.3) 71.6 (8.5) 0.515
Sex (male/female) 37/13 49/33 32/18 0.248
Creatinine (lmol/l) 103 (51) 88 (24) 87 (15) 0.017
eGFR (ml/min/1.73) 64 (21) 69 (16) 70 (10) 0.086
TEG indices
R (min) 4.9 (1.5) 8.6 (4.0) 7.8 (4.6) \0.001a
K (min) 1.3 (1.07–1.72) 1.8 (1.47–2.2) 1.8 (1.5–2.3) \0.001a
Angle () 69.2 (7.0) 63.1 (8.2) 60.9 (11.0) \0.001a
MA (mm) 67.9 (6.1) 65.3 (7.3) 63.4 (12.8) 0.038
TMA (min) 23.9 (3.5) 28.6 (6.0) 28.5 (7.0) \0.001a
G (d/s/103) 11.2 (3.5) 9.9 (2.8) 9.8 (3.5) 0.042a
E (d/s) 224 (71) 199 (56) 195 (69) 0.042a
TPI (s) 93 (55) 61 (35) 60 (42) \0.001a
A30 (mm) 65.8 (6.8) 63.2 (7.3) 62.3 (12.7) \0.001a
CL30 (%) 96.8 (2.8) 96.9 (2.6) 98.1 (2.1) 0.01b
LY30 0.55 (0.2–1.3) 0.65 (0.1–1.4) 0.10 (0.0–0.60) 0.004b
A60 (mm) 61.7 (6.9) 59.4 (7.1) 59.2 (11.9) 0.277
CL60 (%) 90.7 (3.7) 91.0 (4.3) 93.5 (4.1) 0.001b
LY60 (%) 3.5 (2.4–5.1) 3.3 (1.8–5.2) 2.0 (0.9–3.5) 0.002b
A (mm) 61.6 (6.9) 58.9 (9.3) 59.4 (11.3) 0.248
CI (arbitrary units) 2.0 (0.47–3.4) -0.7 (-2.7–1.1) 0 (-2.2–1.3) \0.001a
MPA indices
L time (min) 5.5 (4.8–6.0) 9.6 (7.8–13.0) 8.3 (6.8–9.5) \0.001a
RCF (units/s) 39.8 (36.5–44.3) 15.5 (9.6–26.2) 14.3 (9.5–21.6) \0.001a
MOD (units) 0.49 (0.1) 0.39 (0.13) 0.39 (0.09) \0.001a
RCD (units/s) 37.8 (10.1) 41.4 (16.5) 43.4 (18.3) 0.194
T50 (min) 4.4 (0.75) 3.0 (0.7) 3.4 (0.4) \0.001c
Data presented as mean (standard deviation) or median (interquartile range). p values by analysis of
variance or the Kruskall–Wallis test. eGFR estimated glomerular filtration rate. Between group analysis by
Tukey’s post hoc test
a p\ 0.05 between aspirin and the two other groups
b p\ 0.05 between warfarin and the two other groups
c p\ 0.05 between all three groups
Effects of non-vitamin K antagonist oral anticoagulants… 541
123
the TEG method and, therefore, add confusion. We also
acknowledge the potential effects of other medications, and
of other pathology (such as inflammation and lipids) [20]
that may influence fibrin clot structure (although we have
excluded age, sex, body mass index and renal function as
major influences). In this respect an animal model has
suggested that rivaroxaban reduced levels of inflammatory
cytokines [21]. A further limitation is we cannot factor in
the levels of fibrinogen or the actual amount of each drug in
the patient’s blood, and we were unable to determine the
actual mass of each NOAC in the patient’s blood. This
pertinent for the dabigatran data as active drug in the
plasma may act on exogenously-added thrombin in the
MPA. Nevertheless, our data point to marked differences in
the extent to which selected TEG and MPA indices are
influenced by warfarin and the NOACs, as are summarised
in Table 5. Some of these differences are likely to reflect
whole blood versus fibrin clot formation, as it is established
that platelets contribute to a fibrin clot [22, 23], although
our control group are taking at least 75 mg of aspirin daily,
and this drug may also influence lysis by tPA [24]. Our data
also point to marked differences between the effects of the
NOACs, suggesting that dabigatran is a more effective
agent than apixaban and in one respect, than rivaroxaban.
However, one index suggests that rivaroxaban may be
more effective that the other agents, whilst another index
Table 4 Analysis according to
NOAC
Apixaban (n = 17) Dabigatran (n = 19) Rivaroxaban (n = 46) p
Clinical and demographic
Age (years) 76.9 (10.6) 73.9 (9.2) 72.1 (10.6) 0.262
Sex (male/female) 8/9 15/4 26/20 0.119
Creatinine (lmol/l) 86 (30) 90 (22) 88 (21) 0.879
eGFR (ml/min/1.73) 68 (19) 71 (14) 69 (15) 0.832
TEG indices
R (min) 6.7 (1.6) 10.7 (5.9) 8.5 (3.2) 0.009a
K (min) 1.7 (0.6) 2.2 (0,9) 2.0 (0.8) 0.175
Angle () 64.4 (8.4) 60.9 (7.9) 63.5 (8.2) 0.371
MA (mm) 66.2 (6.5) 64.7 (5.8) 65.1 (8.1) 0.828
TMA (min) 25.0 (2.9) 31.9 (7.7) 28.5 (5.4) 0.002a
G (d/s/103) 10.3 (2.6) 9.6 (2.6) 10.0 (3.0) 0.760
E (d/s) 205 (52) 192 (53) 199 (60) 0.760
TPI (s) 74 (45–109) 38 (30–63) 56 (40–75) 0.063
A30 (mm) 64.3 (6.6) 62.5 (5.9) 63.1 (8.1) 0.756
CL30 (%) 97.2 (2.7) 96.6 (2.2) 96.8 (2.9) 0.794
LY30 0.4 (0.05–1.1) 0.7 (0.3–2.0) 0.6 (0.1–1.3) 0.574
A60 (mm) 60.9 (6.2) 58.7 (6.2) 59.2 (7.9) 0.631
CL60 (%) 92.0 (4.2) 90.2 (3.8) 91.0 (4.5) 0.440
LY60 (%) 3.0 (1.4–4.2) 3.7 (2.0–6.1) 3.25 (1.8–4.9) 0.772
A (mm) 60.9 (6.2) 58.6 (6.2) 59.4 (7.5) 0.610
CI (arbitrary units) 2.0 (-0.8–2.8) -2.0 (-5.0–0.1) -0.7 (-2.5–0.7) 0.002a
MPA indices
L time (min) 8.0 (7.6–9.2) 23.0 (9.8–30.3) 9.8 (7.8–12.1) \0.001b
RCF (units/s) 22.0 (20.0–29.0) 28.5 (16.2–30.7) 12.4 (7.0–15.3) \0.001c
MOD (units) 0.37 (0.09) 0.27 (0.09) 0.44 (0.13) \0.001b
RCD (units/s) 51.8 (13.9) 42.6 (12.1) 36.8 (17.3) 0.005d
T50 (min) 2.9 (0.45) 3.3 (0.37) 2.9 (0.75) 0.161
Data presented as mean (standard deviation) or median (interquartile range). p values by analysis of
variance or the Kruskall–Wallis test. eGFR estimated glomerular filtration rate. Between group analysis by
Tukey’s post hoc test
a p\ 0.05 between apixaban and dabigatran
b p\ 0.05 between dabigatran and the two other groups
c p\ 0.05 between rivaroxaban and the two other groups
d p\ 0.05 between apixaban and rivaroxaban
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points to a weaker effect than apixaban. These variable
effects cannot immediately be ascribed to the mode of
action of the NOACs, that is, thrombin inhibition versus
Factor Xa inhibition, and so may be specific to each
NOAC.
Conclusions
Our data suggests that the TEG and MPA methods may
bring useful information in determining more precisely the
mechanisms by which warfarin (as certain TEG and MPA
indices correlate with the INR) and NOACs protect against
thrombosis. However, the clinical value of these data is as
yet unknown and can only be answered by prospective
outcome studies linking these indices to clinical outcomes
such as in-stent thrombosis [25].
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